Money shot from the Investor Day presentation. A 9 month lag from opportunity to contract is typical.

This won't directly translate to revenue growth - since large phase 3 AD contracts have a disproportionately large impact. However it does highlight the inroads they're making into other diseases. The tailwinds appear to be the reputational uplift they've gained from delivering Lilly's massive Donanemab phase 3 trials, the partnership with Medidata, putting more focus into other trials outside of AD, and a general positive sentiment shift in the biotech sector.

@Slew will see you there! I’ll be the one in black “barefoot” shoes.